U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H24F3N5O3.C7H8O3S
Molecular Weight 743.751
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UMBRALISIB TOSYLATE

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.CC(C)OC2=CC=C(C=C2F)C3=NN([C@@H](C)C4=C(C5=CC(F)=CC=C5)C(=O)C6=C(O4)C=CC(F)=C6)C7=C3C(N)=NC=N7

InChI

InChIKey=KYJWUPZPSXZEPG-NTISSMGPSA-N
InChI=1S/C31H24F3N5O3.C7H8O3S/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29;1-6-2-4-7(5-3-6)11(8,9)10/h4-16H,1-3H3,(H2,35,36,37);2-5H,1H3,(H,8,9,10)/t16-;/m0./s1

HIDE SMILES / InChI
Umbralisib (TGR-1202) is an orally available PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-cell lymphocytes. Inhibition of PI3K delta signaling with umbralisib has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies. Umbralisib is currently in Phase 3 clinical development in combination with Ublituximab for patients with hematologic malignancies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
22.2 nM [EC50]
Target ID: P49674
Gene ID: 102800317|||1454
Gene Symbol: CSNK1E
Target Organism: Homo sapiens (Human)
Target ID: O00329
Gene ID: 5293.0
Gene Symbol: PIK3CD
Target Organism: Homo sapiens (Human)
6.2 nM [Kd]
Target ID: P49674
Gene ID: 102800317|||1454
Gene Symbol: CSNK1E
Target Organism: Homo sapiens (Human)
180.0 nM [Kd]
PubMed

PubMed

TitleDatePubMed
Can umbralisib bring PI3Kδ out of the shadows?
2018 Apr
Umbralisib Inhibits PI3Kδ with Less Toxicity Than Previous Inhibitors.
2018 Apr
Umbralisib: Treatment for a Rare Lymphoma?
2019 Jun
Patents

Patents

Sample Use Guides

relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: umbralisib orally once daily (400 mg, 600 mg, or 800 mg) and ibrutinib orally once daily (420 mg for chronic lymphocytic leukaemia or 560 mg for mantle cell lymphoma) until disease progression or unacceptable toxicity. Umbralisib plus ibrutinib is well tolerated and active in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a recommended phase 2 dose of umbralisib 800 mg once daily.
Route of Administration: Oral
Umbralisib (TGR-1202), a novel, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 & 24.3 nM, respectively.
Name Type Language
UMBRALISIB TOSYLATE
Common Name English
UKONIQ
Brand Name English
UMBRALISIB TOSYLATE [ORANGE BOOK]
Common Name English
UMBRALISIB TOSYLATE [USAN]
Common Name English
TGR-1202 (4-METHYLBENZENESULFONATE)
Code English
Umbralisib tosylate [WHO-DD]
Common Name English
RP-5307
Code English
2-[(1S)-1-{4-Amino-3-[3-fluoro-4-(propan-2-yloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one mono(4-methylbenzenesulfonate)
Systematic Name English
4H-1-BENZOPYRAN-4-ONE, 2-((1S)-1-(4-AMINO-3-(3-FLUORO-4-(1-METHYLETHOXY)PHENYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)ETHYL)-6-FLUORO-3-(3-FLUOROPHENYL)-,4-METHYLBENZENESULFONATE
Official Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
NCI_THESAURUS C2152
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
Code System Code Type Description
USAN
CD-145
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
CAS
1532533-72-4
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545267
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
PUBCHEM
86707828
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
DAILYMED
FU8XW5V3FS
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
SMS_ID
300000013063
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
FDA UNII
FU8XW5V3FS
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
RXCUI
2478438
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY
NCI_THESAURUS
C152795
Created by admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
PRIMARY